¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mating type gene"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene analysis
    À¯ÀüÀںм®
  • gene cloning
    À¯ÀüÀÚŬ·Î´×, À¯ÀüÀÚº¹Á¦
  • gene conversion
    À¯ÀüÀÚÀüȯ
  • gene defect
    À¯ÀüÀÚ°á¼Õ
  • gene deletion
    À¯ÀüÀÚ°á¼Õ
  • gene dosage compensation
    À¯ÀüÀÚ¿ë·®º¸»ó
  • gene expression
    À¯ÀüÀÚ¹ßÇö
  • gene family
    À¯ÀüÀÚ±º
  • gene frequency
    À¯ÀüÀÚºóµµ
  • gene genetics
    À¯ÀüÀÚÀ¯ÀüÇÐ
  • gene imbalance
    À¯ÀüÀÚºÒÆòÇü
  • gene map
    À¯ÀüÀÚÁöµµ
  • gene mapping
    À¯ÀüÀÚÀ§Ä¡ÁöÁ¤, À¯ÀüÀÚÁöµµÀÛ¼º
  • gene pool
    À¯ÀüÀÚÇ®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕÇ׿øÀ¯ÀüÀÚ
  • hox gene
    Ȥ½ºÀ¯ÀüÀÚ
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
  • major histocompatibility gene
    ÁÖÁ¶Á÷ÀûÇÕ¼ºÀ¯ÀüÀÚ
  • marker gene
    Ç¥ÁöÀ¯ÀüÀÚ
  • modulator gene
    ÀÛµ¿À¯ÀüÀÚ, ¸Å°³À¯ÀüÀÚ
  • molecular check point gene
    ºÐÀڰ˹®À¯ÀüÀÚ
  • mutant gene
    µ¹¿¬º¯ÀÌÀ¯ÀüÀÚ
  • mutator gene
    º¯ÀÌÀ¯¹ßÀ¯ÀüÀÚ
  • nucleolar gene
    ÇÙ¼ÒüÀ¯ÀüÀÚ
  • operator gene
    ÀÛµ¿À¯ÀüÀÚ
  • recessive gene
    ¿­¼ºÀ¯ÀüÀÚ
  • regulator gene
    Á¶ÀýÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Lafora body type of myoclonus
    ¶óÆ÷¶ó üÇü ¸¶ÀÌ¿ÀŬ·Î´©½º.
  • Lutheran s type
    ·çÅ×¶õÇü.
  • Mobitz type I SA block
    ¸ðºñÃ÷ ¥°Çü µ¿¹æÂ÷´Ü.
  • Mobitz type II AV block
    ¸ðºñÃ÷ ¥±Çü ¹æ½ÇÂ÷´Ü.
  • Mobitz type II SA block
    ¸ðºñÃ÷ ¥±Çü µ¿¹æÂ÷´Ü.
  • Ogawa type
    ¿À°¡¿ÍÇü
  • RF coil type
    °íÁÖÆÄ ÄÚÀÏ À¯Çü
  • T-type channel
    T-Çü Åë·Î
  • aberrant type
    ÀÌÇü(ì¶úþ)
  • abortive type
    ºÎÀüÇü(ÝÕîïúþ).
  • acute fulminating type
    ±Þ¼º Àü°ÝÇü.
  • agammaglobulinemia,x-linked, bruton type
    ¼º¿°»öü ¿¬°ü¼º, ºê·çÅæÇü(àõæøßäô÷ æáμàõ, ¡­úþ)
  • anovulatory type
    ¹«¹è¶õÇü
  • glomus type of arteriovenous anastomosis
    Å丮Çüµ¿Á¤¸Æ¿¬°á
  • golgi type i neuron
    ±äÃà»è½Å°æ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gene map
    À¯ÀüÀÚÁöµµ
  • gene map order
    À¯ÀüÀÚÁöµµ¼ø¼­
  • gene mutation
    ÇØºÎ
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ(ÔÍæÔܨì¶).
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
  • gene mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ.
  • gene mutation
    À¯ÀüÀÚ(µ¹¿¬)º¯ÀÌ
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ(î¢ðÚùê).
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ.
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ
  • gene recombination
    À¯ÀüÀÚÀçÁ¶ÇÕ
  • gene redundancy
    À¯ÀüÀÚÁߺ¹, À¯ÀüÀÚ¿©À¯
  • gene regulation
    À¯ÀüÀÚÁ¶Àý(ðàï½).
  • gene regulation
    À¯ÀüÀÚÁ¶Àý.
  • gene replacement
    À¯ÀüÀÚ±³È¯
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • gene library
    À¯ÀüÀÚ(ë¶îîí­) ¶óÀ̺귯¸®
  • gene linkage
    À¯ÀüÀÚ ¿¬°ü(ë¶îîí­Ö¤Î¼)
  • gene locus
    À¯ÀüÀÚ ºÎÀ§(ë¶îîí­Ý»êÈ)
  • gene mapping
    À¯ÀüÀÚ ÀÛµµ(ë¶îîí­íÂÓñ)
  • gene pair
    À¯ÀüÀÚ ½Ö(ë¶îîí­äª)
  • gene pool
    À¯ÀüÀÚ(ë¶îîí­) Ç®
  • gene product
    À¯ÀüÀÚ(ë¶îîí­) »ê¹°
  • gene reduncdancy
    À¯ÀüÀÚ Áߺ¹(ë¶îîí­ñìÜÜ)
  • gene reiteration
    À¯ÀüÀÚ Áߺ¹(ë¶îîí­ñìÜÜ)
  • gene repetition
    À¯ÀüÀÚ ¹Ýº¹(ë¶îîí­ÚãÜÖ)
  • gene splicing
    À¯ÀüÀÚ(ë¶îîí­) ½ºÇöóÀ̽Ì
  • gene substitution
    À¯ÀüÀÚ Ä¡È¯(ë¶îîí­öÇüµ)
  • gene synthesis
    À¯Àü»ç ÇÕ¼º(ë¶îîí­ùêà÷)
  • gene therapy
    À¯ÀüÀÚ Ä¡·á(ë¶îîí­ö½Öû)
  • gene transfection
    À¯ÀüÀÚ ÀÌÀÔ(ë¶îîíºì¹ìý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CRYG gamma crystallin gene
din damage inducible [gene]
DMGT deoxyribonucleic acid-mediated gene transfer
FHIT fragile histidine triad [gene]
GAG glycosaminoglycan; group-specific antigen gene
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CGRP-IR Calcitonin gene-related peptide-like immunoreactivity
CGRP Calcitonin gene-related polypeptide
CAP Catabolite gene activator protein
CAT Choramphenicol Acetyltransferase gene
CMGT Chromosome mediated gene transfer
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • monocytic type
    ´ÜÇÙ±¸Çü
  • morphea-like type
    ¹Ý»ó °æÇÇÁõ °°Àº ÇüÅÂ
  • multifocal type
    ´Ù¹ß¼º
  • muscle tension type headache
    ±Ù ±äÀ强 µÎÅë
    ÈĵκÎ, Ç׺ÎÀÇ Áö¼ÓÀûÀÎ ¾Ð¹Ú°¨, ±³¾×°¨À» È£¼ÒÇÑ´Ù. ÀÌ ÁõÀÇ È¯ÀÚ´Â ½Å°æÁú·Î ±äÀåÇϱ⠽¬¿î »ç¶÷¿¡°Ô ¸¹°í °³Ã¼ÀÇ ±Ù±äÀ强¼ÒÀΰú ¾î¿ï¾îÁ® ±ÙÀÇ Áö¼ÓÀû ¼öÃà°ú ±ÙÀÇ ¼øÈ¯ ºÎÀü ¡æ ÅëÁõ ¹°Áú ¹ß»ý ¡æ ÅëÁõ ¡æ ±Ù ¼öÃàÀ̶ó´Â ¾Ç¼øÈ¯ÀÌ Çü¼ºµÇ´Â °ÍÀ¸·Î »ý°¢µÈ´Ù. Á÷¾÷¿¡ µû¸¥ ºÎÀÚ¿¬½º·¯¿î ÀÚ¼¼°¡ °ü·ÃÀÌ ÀÖ´Â °æ¿ìµµ ¸¹°í ½Åü, ½É¸®Àû ¾çÃø¸éÀ¸·ÎºÎÅÍÀÇ Á¢±ÙÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹´Ù.
  • muscular type of vein
    ±ÙÀ°Çü Á¤¸Æ
  • nonnecrotizing type
    ºñ±«»ç¼º ÇüÅÂ
  • oral-facial-digital syndrome, type I
    IÇü±¸-¾È¸é-ÁöÁõÈıº
    X-¿¬°ü¼º ¿ì¼º À¯Àüº´À¸·Î¼­ ³²ÀÚ¿¡°Ô´Â Ä¡¸íÀûÀ¸·Î ±¼ÁöÁõ, ´ÙÁöÁõ, ÇÕÁöÁõ µîÀÌ Æ¯Â¡À̸ç, µÎ°³, ¾È¸é, ¼³, ±¸°³ ¹× ÇÏ¾Ç ±âÇüÀ» ¼ö¹ÝÇϰųª Áö´É ÀúÇÏ, Å»¸ðÁõ, ¾È¸é Áö·ç¸¦ ¼ö¹ÝÇÑ´Ù.
  • pedunclated type
    À¯°æÇü
  • personality type
    Àμº
  • pontic of root extension type
    À¯±Ù °¡°øÃ¼
    ¼ÒÇüÀÇ Ä¡±ÙÀ» °¡Áö°í ¹ßÄ¡¿Í ¼Ó¿¡ ÀûÇյǴ °¡ °øÃ¼, Ä¡°æºÎ¿Í ÇüÅ ±×¸®°í Ä¡Àº¿¬°úÀÇ °ü°è°¡ ÀÚ¿¬¿¡ °¡±õ°í ½É¹ÌÀûÀÌ°í °¡Àå ¿ì¼öÇϸç, ÀåÂø ÈÄ Ä¡ÀºÀÌ ¾à°£ ÅðÃàÇÏ¿©µµ °¡°øÃ¼¿ÍÀÇ »çÀÌ¿¡ °ø±ØÀÌ »ý±âÁö ¾Ê°í »ç¿ë°¨µµ ¾çÈ£ÇÏ´Ù. ´ë°³ Áï½Ã °¡°ø ÀÇÄ¡·Î¼­ ¹ßÄ¡ Á÷ÈÄ¿¡ ÀåÂøµÈ´Ù.
  • precision type attachment
    Á¤¹ÐÇü ºÎÂø ÀåÄ¡
  • pseudohypertrophic type
    °¡¼º ºñ´ëÇü
  • recurring type
    Àç¹ß¼º
  • repository type of penicillin
    ÀúÀåÇü Æä´Ï½Ç¸°
  • salivary gland type
    Ÿ¾×¼± À¯Çü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
gene products, gag Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen.
(12 Dec 1998)
gene products, nef Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor.
(12 Dec 1998)
gene products, pol Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase.
(12 Dec 1998)
gene products, rev Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion.
(12 Dec 1998)
gene products, rex Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr.
(12 Dec 1998)
gene products, tat Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription.
(12 Dec 1998)
gene products, tax Transcriptional trans-acting proteins of the promoter elements found in the long-terminal repeats (ltr) of HTLV-I and HTLV-II. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the ltr.
(12 Dec 1998)
gene products, vif A 23 kD regulatory protein important for virion infectivity in HIV. The protein is found in the cytoplasm of HIV-infected cells and is not absolutely required for virion formation.
(12 Dec 1998)
gene products, vpr Trans-acting proteins which accelerate virus replication in HIV. The vpr proteins act in trans to increase the levels of HIV specified proteins. Vpr is short for viral protein r, where r is undefined.
(12 Dec 1998)
gene products, vpu Non-glycosylated, membrane-associated, 16 kD proteins which are expressed in large amounts in cells infected with HIV-1. The proteins are required for efficient virion maturation and release. They are not present in HIV-2 nor in siv. Vpu is short for viral protein u, with u undefined.
(12 Dec 1998)
gene rearrangement A structural alteration of a chromosome that causes a change in the orderof its loci.
(09 Oct 1997)
gene rearrangement, alpha-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, beta-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the beta-chain of antigen receptors.
(12 Dec 1998)
gene rearrangement, b-lymphocyte Ordered rearrangement of b-lymphocyte variable gene regions coding for the immunoglobulin chains, thereby contributing to antibody diversity. It occurs during the differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, heavy chain Ordered rearrangement of b-lymphocyte variable gene regions thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á